

## Preliminary Scientific Program

as at 2 October 2019, subject to change

### Monday 25 November 2019

08:30 – 17:00	Beginner Population Approach workshop (Pharmacometrics)	Intermediate Population Approach workshop (Pharmacometrics)
17:00 – 17:45	PAGANZ AGM	
18:00 – 19:30	ASCEPT Board meeting	

### Tuesday 26 November 2019

08:00 – 18:00	Registration desk open		
08:30 – 12:30	Innovation and impact workshop (09:00 – 12:30) Chair: Prof Kevin Pflieger	Pharmacogenomics workshop (10:30 – 12:30) Chair: Prof Andrew Somogyi	Clinical Pharmacology workshop (08:30 – 12:30 including AGM)
	<p>Innovation and impact workshop</p> <p><b>Accelerating Australia</b></p> <p>Supported by <b>MTPConnect</b> MedTech and Pharma Growth Centre</p> <p>Including an introduction to SPARK Prof Michael Wallach, Director, SPARK Oceania</p> <p><b>SPARK Oceania</b></p>	<p>10:30 – 10:35 <b>Welcome &amp; introduction</b> Prof Andrew Somogyi, Chair ASCEPT Pharmacogenomics SIG</p> <p>10:35 – 11:15 <b>Application of new tools to understand the genetics of adverse drug reactions</b> Prof Martin Kennedy, Carney Centre for Pharmacogenomics, University of Otago, Christchurch, New Zealand</p> <p>11:15 – 11:40 <b>Precision medicine for type 2 diabetes</b> Assoc Prof Rinki Murphy, University of Auckland, Auckland, New Zealand</p> <p>11:40 – 12:05 <b>ECR/student talks</b></p> <p>12:05 – 12:30 <b>Pharmacogenomics SIG AGM</b></p>	
12:30 – 13:30	Break (delegates to make their own arrangements for lunch at their expense)		
13:30 – 16:30		<p><b>Education Forum</b></p> <p>Showcase of teaching initiatives</p> <p>Round table discussion of issues in pharmacology education</p> <p><b>Education Forum AGM</b></p>	<p><b>Neuropharmacology/Drug Discovery workshop</b></p> <p>13:30 – 14:45 Student and ECR talks</p> <p>14:45 – 15:00 Comfort break</p> <p>15:00 – 16:15 Student and ECR talks</p> <p>16:15 – 16:30 Drug Discovery SIG Meeting Neuropharmacology SIG meeting</p>
16:30 – 17:00	Comfort break		
17:00 – 18:00	<p><b>Conference opening and keynote address</b></p> <p>Prof Donald Mager, University of Buffalo, USA</p>		
18:00 – 19:30	<p><b>Welcome reception</b></p> <p>Reds Bar, Rydges Lakeland Resort</p>		

## Wednesday 27 November 2019

07:30 – 18:00	Registration desk open		
08:00 – 09:00	<b>ASCEPT Rand Medal lecture</b> <b>Molecular and structural basis of the allosteric control of GPCR phenotype by receptor activity-modifying proteins (RAMPs)</b> Prof Patrick Sexton, Monash Institute of Pharmaceutical Sciences, Monash University		
09:00 – 10:30	<b>Oral presentations 1: Cardiovascular</b>	<b>Oral presentations 2: Pharmacoepidemiology</b>	<b>Oral presentations 3: Pharmacometrics and Clinical Pharmacology</b>
09:00 – 09:15	<b>Both <math>\beta</math>1- and <math>\beta</math>2-adrenoceptors mediate arrhythmic contractions, ryanodine receptor channel opening and phosphorylation in human failing hearts: Control by PDE3</b> Assoc Prof Peter Molenaar, Queensland University of Technology, Australia	<b>Efficacy and safety of tapentadol immediate release for acute pain: A systematic review and meta-analysis</b> Miss Xinyi Wang, The University of Sydney, Australia	<b>A population pharmacokinetic model of mycophenolic acid using dual-phase absorption and plasma protein binding</b> Dr David Metz, The University of Melbourne, Australia
09:15 – 09:30	<b>Characterising prolonged high fat diet as a model of obesity-induced left ventricular diastolic dysfunction in mice</b> Dr Miles De Blasio, Baker Heart and Diabetes Institute, Australia	<b>Prevalence of adverse drug events and adverse drug reactions in hospital among older patients with dementia: A systematic review</b> Miss Marissa Sakiris, The University of Sydney, Australia	<b>A population pharmacokinetic model for metformin in patients receiving intermittent haemodialysis</b> Miss Klarissa Sinnappah, University of Otago, Dunedin, New Zealand
09:30 – 09:45	<b>Mechanisms underlying cognitive impairment during small vessel disease</b> Dr Michael De Silva, La Trobe University, Australia	<b>Missing data reporting in clinical pharmacy research</b> Dr Sujita Narayan, The University of Sydney, Australia	<b>External evaluation of published population pharmacokinetic models of tacrolimus in adult heart transplant recipients</b> Ms Ranita Kirubakaran, University of New South Wales, Australia
09:45 – 10:00	<b>Impact of diabetes on the murine cardiac cellular landscape and systemic leukocyte proportions</b> Mr Charles Cohen, Baker Heart and Diabetes Institute, Australia	<b>Pharmacological treatment dynamics in people initially prescribed metformin or sulfonylurea for type 2 diabetes</b> Mr Stephen Wood, Monash University, Australia	<b>Systematic literature review comparing target concentration intervention to therapeutic drug monitoring of vancomycin therapy</b> Mr Guangda Ma, The University of Auckland, New Zealand
10:00 – 10:15	<b>Effects of long-term polypharmacy and deprescribing on cardiovascular function and cardiac structure in aged mice</b> Ms Trang Tran, Kolling Institute of Medical Research, The University of Sydney, Australia	<b>Prevalence and determinants of adverse drug reactions associated with opioid medications in older patients</b> Mr Aymen Alqurain, University of South Australia, Australia	<b>Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure</b> Dr Sophie Stocker, St Vincent's Hospital, Sydney, Australia
10:15 – 10:30	<b>Cardiomyocyte ErbB4 receptor deletion causes rapid-onset cardiac failure in neonatal mice</b> Dr Melissa Reichelt, The University of Queensland, Australia	<b>Recommendations of pharmacological alternatives for anticholinergic class of medications prescribed to individuals with dementia</b> Dr Sharmin Bala, University of Otago, New Zealand	<b>Regulatory Pharmacometrics in Australia</b> Dr Mahipal Sinnollareddy, Therapeutic Goods Administration, Australia
10:30 – 11:10	<b>Morning tea with exhibitors</b> <b>Poster presentations</b>		

11:15 – 13:15	<b>Symposium 1: Novel pharmacotherapies for cardiopulmonary and respiratory diseases</b>	<b>Symposium 2: Innovative strategies to optimise medicine use in the older population to improve health outcomes</b>	<b>Symposium 3: Molecular control of G protein-coupled receptor efficacy</b>
	<b>Chairs:</b> Assoc Prof Barbara Kemp-Harper, Monash University and Prof Ross Vlahos, RMIT University, Australia	<b>Chairs:</b> Prof Sepehr Shakib, University of Adelaide, Australia and Dr Gillian Caughey, University of Adelaide and Royal Adelaide Hospital, Australia	<b>Chairs:</b> Prof Patrick Sexton, Monash University, Australia and Prof Debbie Hay, University of Auckland, New Zealand
11:15 – 11:45	<b>The translational potential of targeting natriuretic peptide-cGMP pathways in the treatment of pulmonary arterial hypertension</b> Prof Adrian Hobbs, William Harvey Research Institute, UK	<b>Complexity and clinical implications of multiple chronic conditions and polypharmacy in the older population</b> Dr Gillian Caughey, University of Adelaide and Royal Adelaide Hospital, Australia	<b>Proximal study of biased agonism at G protein-coupled receptors</b> Dr Peishen (Elva) Zhao, Monash University, Australia
11:45 – 12:15	<b>Pharmacological therapies to target reactivity and remodelling in cardiopulmonary disease</b> Dr Jane Bourke, Monash University, Australia	<b>A multi-country network to improve medicine use in people with Dementia: The NeuroGEN Collaboration</b> Dr Jenni Ilomaki, Monash University, Australia	<b>Unravelling the molecular basis of biased agonism using cryo-EM</b> Assoc Prof Denise Wootten, Monash University, Australia
12:15 – 12:45	<b>Novel therapeutic strategies for the treatment of chronic obstructive pulmonary disease</b> Assoc Prof Chrisan Samuel, Monash University, Australia	<b>Methodological challenges and innovative solutions: Understanding the complexity of pharmacoepidemiological studies in the older population</b> Prof Olaf Klungel, University of Utrecht, The Netherlands	<b>The molecular basis of transmembrane signaling</b> Dr Andrew Kruse, Harvard Medical School, USA
12:45 – 13:15	<b>Targeting pathological inflammation in asthma with G-CSFR antagonists</b> Prof Steven Bozinovski, RMIT University, Australia	<b>Clinical decision support tools for prescribing in the older population: From qualitative dashboards to quantitative modelling and simulation to enable precision dosing</b> Dr Tom Polasek, Certara, Australia	<b>Structural and functional insights into GPCR-beta-arrestin interaction and signaling</b> Dr Arun Shukla, Indian Institute of Technology, India
13:15 – 14:10	<b>Lunch with exhibitors</b> <b>Poster presentations</b>		
14:15 – 15:45	<b>Oral presentations 4: Urogenital and Gastrointestinal</b>	<b>Oral presentations 5: Clinical Trainee and Clinical Pharmacology</b>	<b>Oral presentations 6: Drug Disposition and Response and Pharmacogenomics</b>
14:15 – 14:30	<b>Synthesis of novel P2X1-purinoceptor antagonists for use in male contraception</b> Dr Sab Ventura, Monash University, Australia	<b>Efficacy of endothelin receptor antagonists in patients with the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis</b> Dr Senthuran Shivakumar, Flinders Medical Centre, Australia	<b>Activity and potential biomarkers of evofosfamide in patient-derived and cell line xenograft models of head and neck cancer</b> Dr Stephen Jamieson, University of Auckland, New Zealand
14:30 – 14:45	<b>Exploring allosteric modulation of GPCRs for the treatment of gastrointestinal disorders</b> Dr Jesse DiCello, Monash University, Australia	<b>Use of cannabinoids to manage behaviour in children with developmental/behavioural disorders</b> Dr Angela Williams, The University of Queensland, Australia	<b>Effect of CYP2C19 phenotype and physiological differences on the pharmacokinetics of clopidogrel and its metabolites in European and Japanese populations</b> Dr Janna Duong, GlaxoSmithKline, Australia
14:45 – 15:00	<b>Purinergic P2X7 receptor inhibition protects urothelial cells from acrolein-induced cell death, which is independent of oxidative stress</b> Miss Zhinoos Taidi, UNSW, Australia	<b>Clinical outcomes and pharmacokinetic-pharmacodynamic target attainment in patients treated with oral flucloxacillin plus probenecid for staphylococcal infections</b> Dr Philip Drennan, Royal Prince Alfred Hospital, Australia	<b>ADME genes predict cancer patient survival: A comprehensive analysis of 21 different human cancers</b> Dr Dong Gui Hu, Flinders University, Australia

15:00 – 15:15	<b>Age-related changes in histamine receptor mediated contractions of the urinary bladder</b> Miss Zane Stromberga, Bond University, Australia	<b>Polypharmacy in palliative care: A retrospective comparison of two explicit deprescribing tools</b> Dr Richard McNeill, Canterbury District Health Board, Australia	<b>A model to inform in-vivo lignocaine pharmacokinetics from a controlled release device</b> Dr Jacqueline Hannam, University of Auckland, New Zealand
15:15 – 15:30	<b>The impact of ageing on urinary bladder muscarinic receptor activity</b> Assoc Prof Christian Moro, Bond University, Australia	<b>Monitoring for valproate toxicity in patients with hypoalbuminemia</b> Dr Arushi Madan, Royal Brisbane & Women's Hospital, Australia	<b>Assessment of inter-ethnic differences in imatinib dosing regimen using physiologically based pharmacokinetic (PBPK) modelling and simulation</b> Mr Jeffry Adiwidjaja, The University of Sydney, Australia
15:30 – 15:45	<b>Erianin induces apoptosis and autophagy in human prostate cancer cell</b> Mr I Gusti Surya C Trapika, The University of Sydney, Australia	<b>Medication adherence in gout: Identifying high-risk patient groups in an Australian clinical setting</b> Mr Chi Mao, University of New South Wales, Australia	<b>Molecular basis of the reduced enzyme activity associated with the cytochrome P450 2C9*3 (Ile359Leu) variant</b> Prof John Miners, Flinders University, Australia
15:45 – 16:10	<b>Afternoon tea with exhibitors</b>		
16:15 – 18:15	<b>Certara New Investigator Award</b> <b>Discovery of novel peptide ligands for orphan G protein-coupled receptors</b> Dr Simon Foster, Monash University, Australia <b>The roles of aerosolized polymyxins in the treatment of lung infections: A step towards dose optimisation</b> Dr Yu-Wei (Wayne) Lin, Monash University, Australia <b>Translational toxicovigilance: Preventing drug related harms through legislation and policy</b> Dr Rose Cairns, The University of Sydney, Australia <b>Gain from pain: Using venomous animals to explore new nociceptive pathways</b> Dr Samuel Robinson, The University of Queensland, Australia		
18:15 – 18:45	<b>ASCEPT New Zealand AGM</b>		



07:30 – 17:00	Registration desk open		
08:00 – 09:30	<b>Oral presentations 7: Inflammation / Respiratory</b>	<b>Oral presentations 8: Drug Discovery</b>	<b>Oral presentations 9: Clinical Pharmacology</b>
08:00 – 08:15	<b>Comparison of two mice models of non-alcoholic steatohepatitis</b> Ms Cheng Peng, The University of Melbourne, Australia	<b>Identification of CXCL17 as an endogenous inhibitor of CXCR4</b> Dr Carl White, University of Nottingham, UK; University of Western Australia, Australia	<b>Australian Breast Device Registry – a model for post-market surveillance of high risk implantable medical devices</b> Dr Ingrid Hopper, Monash University, Australia
08:15 – 08:30	<b>The role of Transforming Growth Factor <math>\beta</math> (TGF<math>\beta</math>) in the response to Influenza A viral infection</b> Miss Julia Chitty, Monash University, Australia	<b>One inhibitor, two mechanisms? Evidence for allosteric regulation of the lipid kinase PI3K<math>\alpha</math></b> Dr Jack Flanagan, University of Auckland, New Zealand	<b>Determining the pre-analytical instability of beta-Lactam antibiotics in therapeutic drug monitoring samples</b> Miss Janni Mortensen, University of Copenhagen, Denmark
08:30 – 08:45	<b>A fresh look at cGMP in innate immune responses</b> Prof Helen Irving, La Trobe University, Australia	<b>Investigating the role of the calcium-sensing receptor in airway contraction using mouse precision cut lung slices</b> Miss Jiayin Diao, Monash University, Australia	<b>Efficacy and Safety of opioid analgesics for acute pain conditions: An overview of systematic reviews</b> Dr Christina Abdel Shaheed, Institute for Musculoskeletal Health; The University of Sydney, Australia
08:45 – 09:00	<b>Effects of prolonged exposure to paracetamol on late gestation rat placenta</b> Miss Yifan Huang, The University of Melbourne, Australia	<b>New strategies to investigate the CC Chemokine Receptor 2 (CCR2) signalling network using phosphoproteomics</b> Dr Simon Foster, Monash University, Australia	<b>Inability of current dosing to achieve carboplatin targets in advanced NSCLC: Impact of systemic inflammation on carboplatin PK and outcomes</b> Assoc Prof Kellie Charles, The University of Sydney, Australia
09:00 – 09:15	<b>Mediators from silica-treated macrophages influence contraction of collagen gels seeded with human lung fibroblasts</b> Ms Claudia Sim, Biomedicine Discovery Institute; Monash University, Australia	<b>Low intrinsic G protein efficacy can explain the improved side effect profile of novel opioid ligands</b> Dr Arisbel Batista Gondin, Monash University, Australia	<b>Economic evidence for deprescribing medications: A systematic review</b> Mr Alexander Clough, The University of Sydney, Australia
09:15 – 09:30	<b>In vivo LPS exposure differentially alters intrapulmonary artery reactivity in mouse precision cut lung slices</b> Miss Emma Lamanna, Monash University, Australia	<b>Orai channel alterations as a consequence of differentiation in a human neural progenitor cell line</b> Ms Silke Chalmers, The University of Queensland, Australia	<b>Substance use in patients with dual diagnosis</b> Dr David Taylor, Eastern Health, Australia
09:30 – 10:00	<b>Early Achievement Award for Women</b>		
10:00 – 10:15	<b>ASCEPT launch of Equity, Diversity and Inclusion Policy</b>		
10:15 – 10:30	<b>Launch morning tea</b>		
10:30 – 11:10	<b>Morning tea with exhibitors Poster presentations</b>		
11:15 – 13:15	<b>Symposium 4: SGLT2 inhibitors: How good are they really?</b>	<b>Symposium 5: Precision medicine in oncology: Beyond diagnosis</b>	<b>Symposium 6: Drug dosing in children – how to do it better!</b>
	<b>Chairs:</b> Dr Jenni Ilomaki, Monash University, Australia and Assoc Prof Matt Doogue, University of Otago, New Zealand	<b>Chairs:</b> Prof Andrew Somogyi, University of Adelaide, Australia and Dr Cornelia Landersdorfer, Monash University, Australia	<b>Chairs:</b> Assoc Prof Noel Cranswick, Royal Children's Hospital, The University of Melbourne, Australia and Prof Jennifer Martin, The University of Newcastle, Australia
11:15 – 11:45	<b>SGLT2 inhibitors: Evidence from RCTs</b> Dr Ingrid Hopper, Monash University, Australia	<b>Precision medicine in lung cancer treatment</b> Prof Mark McKeage, University of Auckland, New Zealand	<b>The principles of dosing, response variability, and dose individualisation challenges in children</b> Dr Hesham Al-Sallami, University of Otago, New Zealand



11:45 – 12:15	<b>SGLT2 inhibitors: Evidence from observational studies</b> Prof Olaf Klungel, Utrecht University, The Netherlands	<b>Establishment of a therapeutic drug monitoring programme for the treatment of childhood cancer patients in the UK</b> Prof Gareth Veal, Newcastle University, UK	<b>Dosing antibiotics: Method development in neonates</b> Dr Amanda Gwee, Royal Children's Hospital, Australia
12:15 – 12:45	<b>Emerging adverse drug reactions related to SGLT2 inhibitors</b> Dr Jenni Ilomaki, Monash University, Australia	<b>Comparison of target concentration intervention dosing tools for busulfan in children</b> Dr Stefanie Hennig, The University of Queensland, Australia	<b>Immunosuppressant dosing in children: Lessons from children and adults</b> Dr David Metz, Royal Children's Hospital, Australia
12:45 – 13:15	<b>SGLT2 inhibitors in clinical practice</b> Assoc Prof Matt Doogue, University of Otago, New Zealand	<b>Predicting severe life-threatening toxicity after fluoropyrimidine drugs</b> Assoc Prof Nuala Helsby, University of Auckland, New Zealand	<b>Biologics use in pregnant women and predicting the effects in their babies</b> Dr Zheng Liu, University of Newcastle, Australia
<b>13:15 – 14:10</b>	<b>Lunch with exhibitors Poster presentations</b>		
<b>14:15 – 15:45</b>	<b>Oral presentations 10: Neuro- and Behavioural Pharmacology and Drug Discovery</b>	<b>Oral presentations 11: Education and Toxicology</b>	<b>Oral presentations 12: ASCEPT Garth McQueen Prize</b>
14:15 – 14:30	<b>Investigating the effects of OxR1 antagonism on goal-directed decision making</b> Mr Jeremy Metha, The University of Melbourne, Australia	<b>Responding the WHO 3rd global patient safety challenge: Development of an inter-professional medication safety education programme</b> Assoc Prof Kellie Charles, The University of Sydney, Australia	<b>Targeting the NLRP3 inflammasome as a novel approach to treat pulmonary hypertension</b> Mrs Tara Scott, Monash University, Australia
14:30 – 14:45	<b>An evaluation of timed snapshot signalling bias analyses for non-equilibrium systems</b> Mr Xiao Zhu, University of Otago, New Zealand	<b>The third iteration of a foundational unit in a new Pharmacy curriculum</b> Dr Betty Exintaris, Monash University, Australia	<b>Influenza A virus provokes maternal vascular dysfunction, inflammation and intrauterine growth restriction</b> Mr Osezua Oseghale, RMIT University, Australia
14:45 – 15:00	<b>Cigarette smoking cessation does not reverse hippocampal-dependent cognitive impairment in mice</b> Dr Simone De Luca, RMIT University, Australia	<b>Multiple choice questions: Can they assess application of knowledge in pharmacology teaching</b> Dr Suong Ngo, The University of Adelaide, Australia	<b>Real-world efficacy and safety outcomes of imatinib treatment in patients with Chronic Myeloid Leukemia: An Australian experience</b> Miss Josephine Touma, The University of Sydney, Australia
15:00 – 15:15	<b>Regulation of ABC lipid transporter expression by oxysterols and cholesterol synthesis intermediates: Implications for Alzheimer's disease</b> Dr Ingrid Gelissen, The University of Sydney, Australia	<b>Developing techniques to isolate and characterise individual Russell's viper venom peptides and proteins</b> Ms Rachael Thomas, University of South Australia, Australia	<b>Identifying and prioritising patients at high-risk of medication harm using risk prediction models</b> Mrs Nazanin Falconer, The University of Queensland, Australia
15:15 – 15:30	<b>Idiosyncratic effects of vigabatrin result from gain-of-function GABAA variants</b> Prof Mary Chebib, The University of Sydney, Australia	<b>The in vitro neurotoxicity of Indian cobra (Naja naja) venom: Efficacy of antivenom</b> Mr Tam Huynh, Monash University, Australia	<b>The M2 macrophage-derived chemokine, CCL18 is elevated in hypertension and promotes vascular fibrosis</b> Miss Mingyu Zhu, Monash University, Australia
15:30 – 15:45	<b>The in vitro biological effects of Cannabichromene enantiomers and analogues</b> Dr Marina Junqueira Santiago, Macquarie University, Australia	<b>Multitask deep learning for metabolism-aware strain-specific assessment of Ames mutagenicity</b> Mr Raymond Lui, The University of Sydney, Australia	<b>Chronic cigarette smoke exposure causes cognitive impairment and neuroinflammation in mice</b> Mr Aleksandar Dobric, RMIT University, Australia
<b>15:45 – 16:10</b>	<b>Afternoon tea with exhibitors</b>		

<b>16:15 – 17:15</b>	<b>Japanese Pharmacological Society keynote address</b>
	<b>Mesoscopic Approaches for Brain Networks: Pharmaceutical and Electroceutical Insights</b> Prof Yuji Ikegaya, The University of Tokyo, Japan
<b>17:15 – 18:15</b>	<b>ASCEPT AGM</b>
<b>19:00 – 23:30</b>	<b>Meeting dinner</b> Skyline Queenstown

## Friday 29 November 2019

<b>08:00 – 12:30</b>	<b>Registration desk open</b>		
<b>08:30 – 09:30</b>	<b>British Pharmacological Society keynote address</b>		
	<b>PBPK-IVIVE: The Trojan Horse that Re-injected Mechanisms Back into Models</b> Prof Amin Rostami-Hodjegan, University of Manchester, UK		
<b>09:30 – 10:25</b>	<b>Morning tea with exhibitors</b> <b>Student poster finalists presentation</b>		
<b>10:30 – 12:30</b>	<b>Symposium 7: Gout: Moving towards centre stage</b>	<b>Symposium 8: Novel therapies for the treatment of stroke and neurological disorders</b>	<b>Symposium 9: Using simulation as a learning tool to develop work place readiness</b>
	<b>Chairs:</b> Prof Richard Day and Dr Sophie Stocker, UNSW Sydney, UNSW Medicine St Vincent's Clinical School, Australia	<b>Chairs:</b> Dr Michael De Silva, La Trobe University, Australia and Dr Lauren May, Monash University, Australia	<b>Chairs:</b> Dr Hesham Al-Sallami, University of Otago, New Zealand and Associate Prof Lynette Fernandes, University of Western Australia, Australia
10:30 – 11:00	<b>Allopurinol at the coal face – can we really get to target with an old drug?</b> Prof Lisa Stamp, University of Otago, New Zealand	<b>Amnion epithelial cell therapy for stroke: Translation of experimental findings into a Phase I clinical trial</b> Prof Chris Sobey, La Trobe University, Australia	<b>Using patient simulation in the lecture theatre to introduce “real-life” scenarios</b> Dr Clare Guilding, Newcastle University Medicine, Malaysia
11:00 – 11:30	<b>Model-based dosing in patients with gout: The curious case of allopurinol</b> Dr Daniel Wright, University of Otago, New Zealand	<b>Tailoring metabotropic glutamate receptor 5 activity with biased allosteric modulators for neurodegenerative disorders</b> Dr Karen Gregory, Monash University, Australia	<b>Using simulations to develop proficiency in the application of pharmacokinetic concepts</b> Dr Cornelia Landersdorfer and Dr David Shackleford, Monash University, Australia
11:30 – 12:00	<b>Off indication medicines and novel strategies with potential to treat gout</b> Prof Anthony Rodgers, UNSW Sydney, The George Institute for Global Health, UNSW Medicine, Australia	<b>The delta-subunit selective GABAA receptor modulator, DS2, improves stroke recovery via an anti-inflammatory mechanism</b> Dr Andrew Clarkson, University of Otago, New Zealand	<b>Clinical Pharmacology Top Trumps for the gamification of student learning about medicines</b> Assoc Prof Matt Doogue, Christchurch Hospital and University of Otago, New Zealand
12:00 – 12:30	<b>What to do about adherence to urate lowering therapy</b> Prof Richard Day, UNSW Sydney, UNSW Medicine St Vincent's Clinical School, Australia	<b>Molecular pharmacology of Cannabinoid Receptor 2, a promising immunomodulatory target</b> Dr Natasha Grimsey, University of Auckland, New Zealand	<b>Real-time simulation to help students become more confident and reflective practitioners</b> Prof Steve Duffull, Otago University, New Zealand
<b>12:30 – 13:00</b>	<b>Awards and meeting close</b>		
<b>13:00 – 13:30</b>	<b>Lunch</b>		